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Abstract
Background: Tracheostomy is recommended for patients receiving mechanical ventilation (MV) for 14 days or
more in the intensive care unit (ICU). Nevertheless, many patients undergoing prolonged MV remain intubated via
the translaryngeal route. The aim of this study was to examine the influence of tracheostomy and persistent
translaryngeal intubation on short-term outcomes in patients mechanically ventilated for ≥14 days.
Methods: A retrospective study was conducted using the admissions database of a 75-bed ICU from January 1,
2012, to December 31, 2012. Patients who required prolonged MV without tracheostomy at the time of initiation of
a ventilator were included. The outcomes were successful weaning, and ICU and in-hospital death. Cox models
were constructed to calculate the influence of tracheostomy on the outcome measures while adjusting for other
potentially confounding factors.
Results: Of the 508 patients requiring prolonged MV, 164 were tracheostomized after a median 18 days of MV.
Patients in whom translaryngeal intubation was maintained had significantly higher ICU (42.7 % versus 17.1 %,
p <0.001) and in-hospital (54.1 % versus 22.0 %, p <0.001) mortality rates, and a significantly lower successful
weaning rate (40.4 % versus 68.9 %, p <0.001). The results were consistent after matching for the propensity
score of performing tracheostomy. Furthermore, a time-dependent covariate Cox model showed that a
tracheostomy was independently associated with lower in-hospital mortality (adjusted hazard ratio [aHR], 0.26;
95 % confidence interval [CI], 0.18–0.39) and higher successful weaning rate (aHR, 2.05; 95 % CI, 1.56–2.68).
Conclusions: Tracheostomy is associated with lower in-hospital mortality and higher successful weaning rates
in ICU patients receiving prolonged MV. However, the cost-effectiveness and long-term outcomes of
tracheostomy for this cohort require further study.
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Background
The number of patients requiring prolonged mechanical
ventilation (PMV) in the intensive care unit (ICU) is in-
creasing [1]. These patients consume a substantial
amount of healthcare resources [2] and most have poor
short- and long-term outcomes [2, 3]. Tracheostomy is
thought to provide several advantages over translaryn-
geal intubation in patients undergoing PMV, such as the
promotion of oral hygiene and pulmonary toilet, im-
proved patient comfort, decreased airway resistance, ac-
celerated weaning from mechanical ventilation (MV) [4],
the ability to transfer ventilator-dependent patients from
the ICU to step-down facilities [5] and a reduced risk of
developing ventilator-associated pneumonia (VAP) [6].
Although tracheostomy is customarily performed to
facilitate care of patients requiring PMV, physician prac-
tices regarding tracheostomy differ widely [7]; further-
more, a significant proportion of patients or family
members decline to give consent for tracheostomy, even
when long-term ventilator dependence is expected. The
reported rates of tracheostomy range from 5–24 % and
time to tracheostomy ranges from 9–12 days [8]. Three
meta-analyses of studies examining the role of tracheos-
tomy in critically ill patients receiving MV have failed to
demonstrate any benefits of “early” tracheostomy on sur-
vival, length of ICU or hospital stay, or duration of MV,
compared with those undergoing “late” tracheostomy or
prolonged translaryngeal intubation [9–11]. It is im-
portant to note, however, that two of these studies
used ≤7 days after translaryngeal intubation as the
definition of “early” tracheostomy [10, 11], while the
other used ≤10 days [9].
Consequently, most experts recommend that tracheos-
tomy be deferred for at least 10–14 days after translaryn-
geal intubation to ensure that ongoing MV is indeed
required [4, 11, 12]. Currently, most clinicians view 1–2
weeks after intubation as the most appropriate timing
for tracheostomy [9]. Nonetheless, many patients still
undergo MV via a translaryngeal endotracheal tube for
more than 2 weeks. We undertook a study to examine
the outcomes of patients undergoing MV for at least
14 days in the ICU via persistent translaryngeal intub-
ation or tracheostomy. We hypothesized that tracheos-
tomy would be associated with an increased rate of
successful weaning and reduced ICU and in-hospital
mortality in critically ill patients requiring PMV com-
pared with persistent translaryngeal intubation. The aim
of this study was to evaluate the effect of tracheostomy
on the outcome of patients receiving PMV (≥14 days) in
our medical-surgical ICU.
Methods
Conduct of the study was approved by the ethics com-
mittee of National Cheng Kung University Hospital
(reference A-ER-103-284-T). It was judged that the
retrospective observational study design posed no risks
to patients. The need for informed consent was waived,
as all data were anonymized and patient identification
numbers were encrypted.
Study design
This was a retrospective cohort study using anonymized
data from an ICU clinical information system (IntelliVue
Clinical Information Portfolio, Philips) derived from a
single center. The database included vital signs and ven-
tilation status recorded automatically from monitors and
ventilators, laboratory data retrieved automatically from
our hospital’s central laboratory report system, fluid bal-
ance, and clinical and nursing procedures. Demographic
data recorded routinely at ICU admission by supervising
nurses included age, sex and the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score. Two
analytical models were constructed: a multivariable time-
dependent Cox model, and propensity score matching for
performing tracheostomy that adjusted for potential con-
founding factors to evaluate the effect of tracheostomy on
the outcomes of patients with PMV.
Patients and setting
Data were obtained from patients admitted to the 75-
bed adult ICU at the tertiary referral center of southern
Taiwan between January 1, 2012, and December 31,
2012. Patients who were older than 16 years and re-
ceived MV ≥24 h were screened, those who underwent
MV for at least 14 days were included in the study.
Patients with a tracheostomy present at the time of initi-
ation of MV were excluded. For patients who had more
than one ICU admission with MV ≥14 days during the
study period, only the first admission was included in
the analyses to avoid the potential selection bias of
including patients without tracheostomy in whom the
risk of death was higher.
In our clinical practice, tracheostomy is normally
undertaken after an episode of failed extubation or rein-
tubation, in the presence of unrelieved upper airway
obstruction, when airway protection or regular pulmon-
ary toilet is indicated, when PMV is needed, or for the
avoidance of the complications of prolonged translaryn-
geal intubation. All tracheostomies are formed surgically.
The decision to perform a tracheostomy is at the discre-
tion of the attending physician, but only after informed
consent has been obtained from the patient, their next
of kin or their legal representative.
Variables
Study variables included in the analyses were: age; sex;
comorbidities; Charlson comorbidity index (CCI) score;
APACHE II score within 24 h of ICU admission; ICU
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type (medical or surgical ICU); presence of a do-not-
resuscitate (DNR) order; time to tracheostomy (if per-
formed); diagnosis at ICU admission; requirement for
non-invasive ventilation (NIV) after extubation; duration
of MV and successful weaning from MV; ICU and hos-
pital lengths of stay; and ICU and in-hospital mortality.
Laboratory data including blood urea nitrogen (BUN),
serum creatinine concentration, blood gas analysis, and
white blood cell (WBC) and platelet counts were re-
corded. In this observational study, we could not
mandate that routine laboratory tests be performed at
particular times. We therefore recorded variables ob-
tained on days 1 to 5 of ICU admission (week 1, w1)
and days 8 to 12 (week 2, w2) to ensure that all data
were available for the analyses. The least favorable value
of each variable was chosen for analysis if more than
two values existed within the same time period. ICU ad-
mission diagnosis and comorbidities were identified ac-
cording to the International Classification of Diseases,
ninth revision and categorized as shown in the supple-
mentary material (Additional file 1). Non-invasive venti-
lation was initiated after extubation as needed, if it was
judged that patients were at high risk of extubation fail-
ure [13–16]. Successful weaning was recorded when MV
was not required again after discontinuation during
hospitalization, regardless of outcome.
Statistical analysis
We categorized the patients into a tracheostomy group
and a translaryngeal tube group. Continuous variables
are expressed as the mean ± standard deviation (SD), or
the median and interquartile range (IQR). Categorical
variables are expressed as frequencies and proportions
(%). Continuous variables were compared with Student’s
t test or the Mann–Whitney U test (for skewed data);
categorical variables were compared with the chi-
squared test or Fisher’s exact test, as necessary. Levels of
significance are expressed as p values; p <0.05 was con-
sidered statistically significant. Demographic, clinical
and laboratory values were used to determine whether
tracheostomy was independently associated with both
in-hospital mortality and successful weaning. As the for-
mation of a tracheostomy was considered to be a time-
dependent covariate, a multivariable time-dependent
Cox model was constructed. Median values were used to
categorize continuous variables for Cox models. The fac-
tors with a p value <0.1 in the univariate analysis, to-
gether with age and sex regardless of the univariate p
value, were entered in the Cox models. The results are
presented as adjusted hazard ratios (aHR) with 95 %
confidence intervals (CIs). The impact of tracheostomy
on outcomes was assessed using a propensity score for a
case-matched comparison to deal with significant het-
erogeneity between patients undergoing tracheostomy or
persistent translaryngeal intubation in a retrospective
cohort study (Table 1). The case-matched comparison
was performed as previously described [17]. All univari-
able predictors of tracheostomy with p <0.25 together
with age and sex were entered into the multivariable
model predicting tracheostomy. Stepwise logistic regres-
sion was performed to remove covariates that had multi-
variable p values of >0.25. A propensity score for
undergoing tracheostomy was calculated for each patient
using the coefficients of the final regression equation.
Then, each tracheostomy patient was matched with a
single translaryngeal intubated patient who had a similar
propensity score (within 0.1 on a scale from 0 to 1).
When more than one matched patient was identified for
a case, the closest admission date was used to select the
matched patient. We also performed a sensitivity ana-
lysis using a more stringent propensity score matching
within 0.05. The matched Wilcoxon test, the McNemar
test, and mixed model or general estimation equations
were used for case-match study comparisons. Analyses
were performed using SPSS, version 20 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
MV was required for at least 24 h in 2,098 adult ICU ad-
missions during the study period. Of these, 551 patients
(26.3 %) who received MV for at least 14 days were
screened, and those who already had a tracheostomy
tube in situ at the initiation of MV were excluded. The
remaining 508 patients were included in the analyses.
During their ICU admission, 164 patients (32.3 %)
underwent a tracheostomy. The remaining 344 patients
(67.7 %) did not undergo a tracheostomy during
hospitalization (Fig. 1). For those who received tracheos-
tomy, the median time between endotracheal intubation
and insertion of a tracheostomy tube was 18 days (IQR,
13–25 days). The overall ICU and in-hospital mortality
rates were 34.4 % and 43.7 %, respectively.
The baseline characteristics of the study population
are summarized in Table 1. A greater proportion of
translaryngeal intubated patients were admitted to the
medical ICU, had a current DNR order, had a higher
CCI score, had chronic heart, liver or connective tissue
disease, and required NIV after extubation, but a smaller
proportion had brain disorders or had sustained trauma.
There were no significant differences in the ratio of the
partial pressure of arterial oxygen to the fraction of
inspired oxygen (PaO2/FiO2), WBC count or platelet
count between the groups. The serum concentrations of
BUN (w2) and creatinine (w1 and w2) were significantly
lower in the tracheostomy group than the translaryngeal
tube group.
Table 2 shows a comparison of the short-term out-
comes between the groups. Compared with those with a
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tracheostomy, translaryngeal intubated patients had sig-
nificantly higher ICU (42.7 % versus 17.1 %, p <0.001)
and in-hospital (54.1 % versus 22.0 %, p <0.001) mor-
tality rates, lower weaning rate (40.4 % versus 68.9 %,
p <0.001) and significantly shorter median duration of
MV (26 days versus 37 days, p <0.001), ICU length of
stay (25 days versus 40 days, p <0.001) and hospital
length of stay (30 days versus 59 days, p <0.001). In
addition, translaryngeal intubated patients were trans-
ferred earlier to lower level regional hospitals com-
pared with tracheostomized patients (28 days versus
54 days, p <0.001).
Multivariable time-dependent Cox regression model-
ing showed that performing a tracheostomy was associ-
ated with a significantly lower risk of in-hospital death
(aHR 0.26, 95 % CI 0.18–0.39, p <0.001) and a signifi-
cantly higher chance of successful weaning (aHR 2.05,
95 % CI 1.56–2.68, p <0.001; Table 3). The other
Table 1 Demographic and clinical characteristics of patients






Age, years 67 ± 14 62 ± 18 0.416
Male, n (%) 203 (59) 110 (67) 0.099
MICU, n (%) 237 (69) 70 (43) <0.001
APACHE II score 23.1 ± 7.8 23.2 ± 7.5 0.446
Do-not-resuscitate order, n (%) 157 (46) 39 (24) <0.001
NIV after extubation, n (%) 79 (23) 24 (15) 0.039
Diagnosis of ICU admission, n (%)
Pneumonia 190 (55) 94 (57) 0.729
Sepsis 164 (48) 68 (42) 0.223
Cardiovascular or vascular
disorder
39 (11) 12 (7) 0.211
Trauma 20 (6) 23 (14) 0.003
Brain disorder 99 (29) 76 (46) <0.001
Burn 5 (2) 0 (0) 0.181
Gastrointestinal Disorder 103 (30) 51 (31) 0.872
CCI score 2 (1–3) 2 (0–3) 0.017
Comorbidities, n (%)
Diabetes 121 (35) 66 (40) 0.313
Chronic lung disease 75 (22) 37 (23) 0.938
Chronic heart disease 91 (27) 29 (18) 0.039
Chronic liver disease 49 (14) 12 (7) 0.036
Chronic renal disease 91 (27) 30 (18) 0.056
Malignancy 107 (31) 44 (27) 0.378
Connective tissue disease 14 (4) 1 (1) 0.045
Neuromuscular disease 19 (6) 10 (6) 0.955
PaO2/FiO2
w1 290.9 ± 136.6 266.6 ± 132.0 0.245
w2 307.9 ± 101.2 293.6 ± 110.0 0.151
WBC (× 103/μl)
w1 12.3 (9.6–16.6) 10.8 (8.4–15.9) 0.808
w2 10.5 (7.9–12.8) 11.5 (7.9–14.9) 0.638
Platelet (× 103/μl)
w1 193.0 (129.0–233.0) 148.0 (102.5–195.3) 0.076
w2 181.0 (107.0–240.0) 143.0 (88.0–263.5) 0.066
BUN (mg/dl)
w1 18.0 (13.0–40.0) 28.5 (14.3–49.8) 0.146
w2 35.0 (24.0–65.0) 44.0 (22.0–65.3) 0.025
Creatinine (mg/dl)
w1 1.1 (0.8–2.0) 1.0 (0.8–2.0) 0.014
w2 1.0 (0.6–2.0) 1.0 (0.6–2.4) 0.020
Data are presented as mean ± standard deviation or median (interquartile
range) unless otherwise stated
Abbreviations: APACHE II Acute physiology and chronic health evaluation II, CCI
Charlson comorbidity index, MICU Medical intensive care unit, NIV Non-
invasive ventilation, BUN Blood urea nitrogen, PaO2/FiO2 ratio of the partial
pressure of arterial oxygen to the fraction of inspired oxygen, WBC White
blood cell count, w1, Data collected within days 1–5 after ICU admission, w2
Data collected within days 8–12 after ICU admission
551 patients with MV ≥ 
14 days were enrolled
508  patients were 
included for study




2,098 adult ICU admission 
with invasive MV ≥ 24 hours 
were screened
344 patients receiving 
persistent translaryngeal
intubation during hospitalization
164 patients undergoing 
tracheostomy during 
hospitalization
Fig. 1 Flow diagram of the study population. Abbreviations: ICU
Iintensive care unit, MV Mechanical ventilation
Table 2 Clinical outcomes of patients receiving mechanical






Duration of MV, days 26 (21–35) 37 (25–51) <0.001
Weaning rate, n (%) 139 (40 %) 113 (69 %) <0.001
Transition to regional
hospitals, n (%)
62 (18 %) 40 (24 %) 0.120
Time to transition, days 28 (21–40) 54 (44–80) <0.001
ICU length of stay, days 25 (20–33) 40 (25–55) <0.001
Hospital length of stay,
days
30 (22–45) 59 (45–94) <0.001
ICU mortality, n (%) 147 (43 %) 28 (17 %) <0.001
Hospital mortality, n (%) 186 (54 %) 36 (22 %) <0.001
Data are presented as median (interquartile range) unless otherwise stated
Abbreviations: MV Mechanical ventilation, ICU Intensive care unit
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independent factors significantly associated with in-
hospital mortality included a DNR order, undergoing
NIV after extubation, malignancy and a PaO2/FiO2
ratio >282 (w2) (Table 3). The other factors inde-
pendently associated with successful weaning included
a DNR order, sepsis, chronic lung disease, APACHE
II score >23, a PaO2/FiO2 ratio >282 (w2) and a
platelet count >140 × 103/μl (w2) (Table 3).
In view of the significant baseline heterogeneity be-
tween the tracheostomy and translaryngeal intubation
groups (see Table 1), we performed a case-matched com-
parison using the propensity score-based algorithm. As
shown in Table 4, except for pneumonia, no significant
differences were found between the two groups concern-
ing ICU admission or clinical characteristics in week 1
or week 2. Similar to the findings before matching,
tracheostomized patients had significantly lower ICU
and hospital mortality rates, a higher successful weaning
rate, longer duration of MV, ICU and hospital stays, and
later transition to regional hospitals (Table 4). In a sensi-
tivity analysis to match the propensity score within 0.05,
139 cases for each group were matched, and the results
were consistent with those described above.
Discussion
We found that patients requiring PMV (≥14 days) who
did not undergo tracheostomy had significantly higher
ICU and in-hospital mortality, and were less likely to be
successfully weaned, after carefully controlling for poten-
tial demographic and clinical confounders. Interestingly,
translaryngeal intubated patients had significantly
shorter durations of MV and ICU and hospital stays
than patients who underwent a tracheostomy. To the
best of our knowledge, this is the first report to have
compared the short-term outcomes of patients who re-
ceived MV for at least 14 days and either underwent
tracheostomy or remained intubated by the translaryn-
geal route for a prolonged period.
We also found that the ICU type, a DNR order, under-
going NIV after extubation, brain disorders and trauma
as the cause of ICU admission, renal function, CCI score
and comorbidities such as chronic heart, liver and con-
nective tissue diseases were associated with the rate and
timing of tracheostomy, findings that are consistent with
a previous report [17]. Our finding that tracheostomy
was independently associated with reduced ICU and in-
hospital mortality rates is also consistent with some pre-
vious reports [17, 18], but not others [19, 20]. Clec'h et
al. [19] reported that tracheostomy had no positive
influence on survival when performed in unselected
mechanically ventilated patients. Their cohort included
patients requiring MV for at least 2 days but nearly half
received MV for <15 days, and therefore their findings
may have been biased by the presence of a subgroup
more likely to have been weaned from MV without the
need for tracheostomy [9]. In contrast, our study in-
cluded only those patients receiving MV for ≥14 days, a
cohort in which failed extubation and severe comorbidi-
ties were more common; a greater proportion would be
expected to require long-term ventilatory support and
would be more likely to benefit from tracheostomy [4].
Similarly, Trouillet and colleagues [20] compared pa-
tients undergoing tracheostomy after 5 days of ventila-
tory support with those intubated by the translaryngeal
route for a prolonged period, and found that tracheos-
tomy did not affect mortality; however, they included pa-
tients ventilated after cardiac surgery who had failed
weaning trials at day 4 of MV and 27 % of the patients
in the prolonged translaryngeal intubation group eventu-
ally underwent a tracheostomy.
In our study, the substantially reduced risk of death
(aHR 0.26) in the tracheostomy group could in part be
Table 3 Factors associated with in-hospital mortality and successful weaning in patients receiving mechanical ventilation for at least
14 days
Hospital mortality Successful weaning
aHR (95 % CI) p value aHR (95 % CI) p value
Performing tracheostomy 0.26 (0.18–0.39) <0.001 2.05 (1.56–2.68) <0.001
Do-not-resuscitate order 2.55 (1.92–3.38) <0.001 0.53 (0.39–0.72) <0.001
NIV after extubation 0.50 (0.35–0.71) <0.001
Malignancy 1.33 (1.01–1.75) 0.044
Sepsis 0.61 (0.47–0.80) <0.001
Chronic lung disease 0.68 (0.50–0.93) 0.016
APACHE II score > 23 0.71 (0.55–0.93) 0.012
PaO2/FiO2 > 282 (w2) 0.73 (0.56–0.96) 0.023 1.34 (1.04–1.73) 0.023
Platelet > 140 × 103/μl (w2) 1.37 (1.05–1.79) 0.020
Abbreviations: aHR Adjusted hazard ratio, APACHE II Acute physiology and chronic health evaluation II, CI Confidence interval, NIV Noninvasive ventilation, OR Odds
ratio, PaO2/FiO2 Ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, w2 Data collected within days 8–12 after ICU admission
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explained by the fact that tracheostomy is associated
with a decreased risk for VAP in patients requiring PMV
[6]. In tracheostomized patients, tracheostomy allows
the vocal cords to close, reduces aspiration of oropha-
ryngeal secretions, reduces bacterial biofilm formation
along the inside of the tracheotomy cannula and facili-
tates weaning from MV. All these factors probably result
in a reduced risk for VAP [6]. Another potential explan-
ation is that ICU physicians may be adept at selecting
candidates for tracheostomy based on the highest prob-
ability of survival, and therefore may provide more ag-
gressive treatment for these patients while being more
likely to offer conservative or palliative treatment to
those intubated by the translaryngeal route for a pro-
longed period. In a retrospective study, it is also possible
that we might have missed some important confounding
factors associated with the decision to undertake trache-
ostomy that might also affect outcomes, even when so-
phisticated adjustment methods such as multivariable
analyses or propensity score-based nested case–control
studies are used.
Aside from tracheostomy, we identified a DNR order,
NIV after extubation, malignancy and a PaO2/FiO2 ratio
(w2) as the factors independently associated with in-
hospital mortality in patients receiving MV for ≥14 days.
There is a body of evidence that using NIV after extuba-
tion improves survival rate in high-risk patients [13–16];
NIV is commonly employed in our clinical practice to
prevent post-extubation respiratory failure. Malignancy
is recognized as a predictor of poor outcome in patients
requiring PMV [3]. Increased PaO2/FiO2 ratio in week 2
might simply reflect a favorable response to treatment,
leading to better outcomes. Furthermore, we found that
tracheostomy was associated with increased successful
weaning rates. In contrast, Wu et al. [18] reported that
tracheostomy has no effect on successful weaning. This
Table 4 Case-matched study: demographic and clinical







Age, years 68 (54–77) 64 (51–74) 0.749
Male, n (%) 108 (66) 110 (67) 0.899
MICU, n (%) 87 (53) 94 (57) 0.464
APACHE II score 24.3 ± 7.4 23.2 ± 7.5 0.448
Do-not-resuscitate order 44 (27) 39 (24) 0.568
NIV after extubation, n (%) 26 (16) 24 (15) 0.871
Diagnosis of ICU admission, n (%)
Pneumonia 75 (46) 94 (57) 0.033
Sepsis 68 (42) 68 (42) 1.000
Cardiovascular or vascular
disorder
13 (8) 12 (7) 1.000
Trauma 17 (10) 23 (14) 0.361
Brain disorder 70 (43) 76 (46) 0.571
Gastrointestinal disorder 42 (26) 51 (31) 0.328
CCI score 2 (1–3) 2 (0–3) 0.836
Comorbidities, n (%)
Diabetes 55 (34) 66 (40) 0.235
Chronic lung disease 36 (22) 37 (23) 1.000
Chronic heart disease 30 (18) 29 (18) 1.000
Chronic liver disease 14 (9) 12 (7) 0.839
Chronic renal disease 35 (21) 30 (18) 0.575
Malignancy 44 (27) 44 (27) 1.000
Connective tissue disease 1 (1) 1 (1) 1.000
Neuromuscular disease 8 (5) 10 (6) 0.804
PaO2/FiO2
w1 302.1 ± 137.7 266.6 ± 132.0 0.899
w2 312.0 ± 101.9 293.6 ± 110.0 0.734
WBC (× 103/μl)
w1 11.9 (9.0–14.4) 10.8 (8.4–15.9) 0.901
w2 10.7 (8.1–12.8) 11.5 (7.9–14.9) 0.449
Platelet (× 103/μl)
w1 181.0 (122.0–226.0) 148.0 (102.5–195.3) 0.516
w2 183.3 ± 100.6 170.1 ± 99.2 0.978
BUN (mg/dl)
w1 18.0 (13.0–35.0) 28.5 (14.3–49.8) 0.774
w2 38.0 (24.0–69.0) 44.0 (22.0–65.3) 0.706
Creatinine (mg/dl)
w1 1.1 (0.8–2.5) 1.0 (0.8–2.0) 0.111
w2 1.3 (0.7–2.4) 1.0 (0.6–2.4) 0.327
Transition to regional
hospitals, n (%)a
39 (24) 40 (24) 0.808
Time to transition, daysb 27 (21–45) 54 (44–80) 0.009
Duration of MV, daysb 28 (21–35) 37 (25–51) <0.001
Weaning rate, n (%)a 65 (40) 113 (69) <0.001
Table 4 Case-matched study: demographic and clinical
characteristics of patients mechanically ventilated for at least
14 days (Continued)
ICU length of stay, daysb 27 (21–34) 40 (25–55) <0.001
Hospital length of stay,
daysb
30 (23–46) 59 (45–94) <0.001
ICU mortality, n (%)a 63 (38) 28 (17) <0.001
Hospital mortality, n (%)a 76 (46) 36 (22) <0.001
Data are presented as median (interquartile range) or mean ± standard
deviation unless otherwise stated
aCompared with general estimation equation analysis, adjusted for pneumonia
bCompared with mixed-model analysis, adjusted for pneumonia
Abbreviations: APACHE II Acute physiology and chronic health evaluation II,
BUN Blood urea nitrogen, CCI Charlson comorbidity index, MICU Medical
intensive care unit, MV Mechanical ventilation, NIV Noninvasive ventilation,
ICU Intensive care unit, PaO2/FiO2 Ratio of the partial pressure of arterial
oxygen to the fraction of inspired oxygen, WBC White blood cell count, w1
Data collected within days 1–5 after ICU admission, w2 Data collected within
days 8–12 after ICU admission
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discrepancy might be explained by a difference in study
setting (ours was conducted in an ICU while theirs took
place in a specialist respiratory care center). Moreover,
tracheostomy has been reported to contribute to facilita-
tion of weaning from MV by decreasing airflow resist-
ance and the associated work of breathing, allowing
clinicians to be more aggressive in their weaning strat-
egies and reducing their concerns about sedation and
reintubation [4]. In addition, we found that a DNR order,
sepsis, chronic lung disease, APACHE II score, PaO2/
FiO2 ratio (w2) and platelet count (w2) were independ-
ently associated with weaning success. These findings
are similar to that of previous studies regarding the pre-
diction of weaning or extubation failure [16]. Platelet
count has also been reported to be associated with suc-
cessful weaning in patients requiring PMV after cardiac
surgery [21]. The relationship between existence of a
current DNR order and poor outcomes can be explained
by the presence of irreversible and terminal diseases.
There have been reports that early tracheostomy was
not associated with a reduced length of ICU stay, hos-
pital stay or duration of MV [9, 10]. Indeed, consistent
with previous studies [17–19], we found that tracheos-
tomy increased the duration of MV and length of ICU
and hospital stays compared with translaryngeal intub-
ation. These observations may be partially explained by
the relatively long median time before tracheostomy
(18 days) in the tracheostomy group. The shorter dur-
ation of MV, and shorter length of ICU and hospital
stays in the translaryngeal intubation group probably re-
flect these patients’ higher mortality rate and earlier
death (30 days compared with 61 days) or transition to
lower-level regional hospitals.
Our study had some limitations. First, we did not rec-
ord data regarding the effects of inadvertent extubation
on the outcomes of the translaryngeal intubated group,
tracheostomy complications, the incidence of extubation
failure or the rate of VAP. All these factors may be asso-
ciated with patient morbidity, mortality and successful
weaning. We did not record serial ICU scores (such as
the daily Sequential Organ Failure Assessment), which
may have more accurately reflected the severity of illness
at the time of tracheostomy (after a median of 18 days
of MV) than the APACHE II score in the first 24 h of
ICU admission [17]. Second, our study was undertaken
retrospectively; this may have caused us to miss import-
ant confounders relevant to the results, while accounting
for the significant heterogeneity between the translaryn-
geal intubation group and the tracheostomy group. Con-
sequently, we cannot completely rule out the possibility
that clinical practice on the ICU tends to select patients
with the highest likelihood of survival for tracheostomy,
although we matched for propensity scores, adjusted
for potential confounders and performed a sensitivity
analysis in which even more stringent propensity score
matching was employed that yielded the same results.
Third, we did not assess the long-term outcomes after
hospital discharge. Further study is needed to determine
whether there are long-term benefits of tracheostomy on
outcomes compared with translaryngeal intubation. A
prospective, randomized controlled study will be needed
to eliminate the biases described above.
Conclusions
Tracheostomy was independently associated with re-
duced ICU and in-hospital mortality, and increased suc-
cessful weaning rate, for critically ill patients requiring
MV for at least 14 days. Tracheostomized patients had a
longer duration of MV and length of ICU and hospital
stays compared with patients who remained intubated
by the translaryngeal route for a prolonged period. The
cost-effectiveness and long-term outcomes of tracheos-
tomy for critically ill patients requiring PMV require fur-
ther study.
Key messages
 For patients requiring MV for at least 14 days,
tracheostomy was significantly associated with
reduced ICU and hospital mortality and increased
successful weaning rate. The results were consistent
after matching for the propensity score of performing
tracheostomy.
 A time-dependent covariate Cox model showed that
tracheostomy was independently predictive of lower
in-hospital mortality and higher successful weaning
rate.
 Our finding that tracheostomized patients required
longer periods of MV, and longer ICU stay and
hospitalization warrants further study to evaluate
the cost-effectiveness and long-term outcomes of
tracheostomy for critically ill patients requiring
PMV.
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